Microbiome Therapeutics prepares to launch ‘microbiome modulator’

By Stephen Daniells contact

- Last updated on GMT

© Getty Images / Nastco
© Getty Images / Nastco

Related tags: Nutrition

After successfully completing a Series B financing, Microbiome Therapeutics is gearing up for the launch of a ‘microbiome modulator’ product designed to help balance the microbiome and support healthy metabolism.

The product, which is a blend of prebiotics, including fermentable fiber (beta-glucan and inulin) and polyphenol antioxidants in a drink mix, will launch in 2018, said the company. A brand name is still under investigation and should be selected soon, a spokesperson for the company told us.

“This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health, in an easy-to-use, flavorful drink mix,” ​said Dale Pfost, acting CEO of MicroBiome Therapeutics. “Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity.”

Findings from those two clinical trials were published in the Journal of Diabetes Science and Technology​ and the Journal of Diabetes and its Complications​.

The spokesperson added that the dietary supplement product will initially launch via e-commerce supported by social media conducted in partnership with New Orleans-based advertising agency Zehnder Communications, plus a network of registered dietitians and certified diabetes educators.  Retail distribution will be built out in the next phase.


The Series B financing raised approximately $1 million. New and existing investors included Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.

“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company,”​ said Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications.

“We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement. Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution.” ​Hunnewell will be joining the board of directors of MBT.

Related news

Related products

show more

Next-wave sports nutrition innovation today

Next-wave sports nutrition innovation today

ADM | 28-Oct-2020 | Technical / White Paper

Today’s consumers are passionate about embracing health in many aspects of their lives, starting with customizing their nutrition. Rooted in proprietary...

ApplePhenon Paper by Renowned Dr William Sears, MD

ApplePhenon Paper by Renowned Dr William Sears, MD

BGG (Beijing Gingko Group) | 13-Oct-2020 | Technical / White Paper

Dr. William Sears, author of over 40 best-selling books and world-renowned media health expert, lends his pen to one of the most exciting ingredients to...

Fermented Soy for Relief of Heartburn Symptoms

Fermented Soy for Relief of Heartburn Symptoms

Lallemand Bio-Ingredients | 08-Oct-2020 | Clinical Study

Gastro-AD® is a food supplement based on non-GMO soy fermented by Lactobacillus strain L. delbrueckii R-187 (Rosell-187). It has an excellent track record...

Biotis™ - Solutions for a good gut feeling

Biotis™ - Solutions for a good gut feeling

FrieslandCampina Ingredients | 07-Oct-2020 | Product Brochure

Discover our range of GOS (galacto-oligosaccharides) with scientifically proven effects to significantly increase levels of ‘friendly bacteria’ in the...

Related suppliers

Follow us


View more